| Bioactivity | P-gp inhibitor 21 (Compound 56) is an inhibitor for P-glycoprotein (P-gp) transport, which reverses P-gp-mediated multidrug resistance (MDR) and exhibits antitumor efficacy in mice without significant cytotoxicity[1]. |
| Invitro | P-gp inhibitor 21 抑制细胞 KBV200 和 NCI/ADR-RES (与 VNR 共同作用) 的增殖，IC50 分别为 2.4 和 27.9 nM[ 1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> P-gp inhibitor 21 相关抗体: |
| In Vivo | P-gp inhibitor 21 (75 mg/kg，腹腔注射) KBV200 异种移植 BALB/c 裸鼠中的肿瘤生长并恢复 MDR 肿瘤对 VNR 的敏感性，且无明显毒性[1]。P-gp inhibitor 21 在小鼠模型中的药代动力学分析[1]route |
| Formula | C27H42N2O4 |
| Molar Mass | 458.63 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yang GZ, et al., Design and Synthesis of Cyclolipopeptide Mimics of Dysoxylactam A and Evaluation of the Reversing Potencies against P-Glycoprotein-Mediated Multidrug Resistance. J Med Chem. 2024 Mar 28;67(6):4560-4582. |